About US
Contact us
-
AstraZeneca oldie Faslodex nets another breast cancer approvalAstraZeneca may have recently hit a snag in the immuno-oncology space, but it got a boost Monday elsewhere in its cancer portfolio. The FDAexpandeduse of Faslodex, granting AZ an indication for solo2017/8/25
-
Allergan heads to federal court to defend Restasis against early generic rivalsIn defense of a top seller, Allergan is squaring off against generics companies in Texas federal court, accusing copycat makersof violating its patent protections on blockbuster eye medication Restasi2017/8/25
-
Allergan hits its already battered Irvine site with another round of job cutsMore than 100 layoffs are on the way at Allergan. The company earlier this month filed a WARNnoticewith state of California,saying it would dismiss 109 employees at its ex-headquarters in Irvine. The2017/8/24
-
Valeant denies bypassing eye-device maker Iconlabs in M&A bid for lens techAfter a disastrous two years for Valeant, the company faces a lawsuit alleging it “engaged in willful ignorance” to bypass a would-be partner and acquire intraocular lens technology from a third-party2017/8/24
-
Alexion wins 3 new Soliris patents as Amgen works on biosimilar of pricey drugWith a Soliris biosimilar showing up in its rearview mirror, Alexion is piling on patents for its superexpensive drug, hoping to put some more distance between it and any sales-grabbing copies. The2017/8/23
-
Johnson & Johnson expected to keep battling talc claims despite losses: expertHaving lost four talc cases worth more than $300 million, Johnson & Johnson is engaged in a tough legal battle against thousands of liability claims alleging routine use caused ovarian cancer. Des2017/8/23
-
Amgen falls short in Epogen patent appeal but Pfizer stumble delays competitionWith a federal appeals decision handed down this week, Amgen has come up short in a legal attempt to defend blockbuster anemia med Epogen from a Pfizer biosim. However, the company’s loss in appeals d2017/8/22
-
CVS, Walgreens and PBMs worked together to gouge consumers, lawsuits claimEven as the generic drug industry works through challenging pricing dynamics, new lawsuits say consumers aren’t realizing all of the benefits from the low prices dragging on the industry’s players. I2017/8/22
-
New Hampshire, 'ground zero' of addiction epidemic, sues Purdue Pharma for overhyping opioidsA number of states fighting opioid addiction have sued top drugmakers, but now New Hampshire has set its sights on a single company. The state filed a civillawsuitagainst Purdue Pharma, maker of OxyCo2017/8/21
-
Expect a Big Pharma ripple effect from United Therapeutics' $210M settlement talks with feds: expertTop pharma players have disclosed federal investigations into their patient assistance contributions, but only United Therapeutics has said it's working ona settlement. That company’s set-aside of $212017/8/21